Brigit Biofarmaka Teknologi Tbk. vs Chandra Asri Pacific Tbk. — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp252 (market cap 172.82B, 218.7K 24h volume), while Chandra Asri Pacific Tbk. trades at Rp2,280 (market cap 194.65T, 735.48M 24h volume). The key difference: Chandra Asri Pacific Tbk. is far larger — about 1126.3× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Chandra Asri Pacific Tbk. is more actively traded (735.48M versus 218.7K). Which is the better fit depends on your goals.
| OBAT | TPIA | |
|---|---|---|
Market Cap | 172.82B | 194.65T |
Volume | 218.7K | 735.48M |
Lot | 2.19K | 7.35M |
Turnover | 53.51M | 1.67T |
Average Price | 244.66 | 2,269.63 |
Value | 53.51M | 1.67T |
Indicative Equilibrium Price | 252 | 2,280 |
Indicative Equilibrium Volume | 48 | 87.05K |
Trailing returns across standard periods
Latest headlines on both assets
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →PT Chandra Asri Petrochemical Tbk formerly PT. Tri Polyta Indonesia, Tbk (the Company) was established under the Domestic Capital Investment Law No. 6 year 1968 and Law No. 12 year 1970 by Notarial Deed No. 40 dated November 2, 1984 of Ridwan Suselo, S.H., notary public in Jakarta. The Company is the largest Indonesia producer of polypropyleneresins that are used in the manufacture of a wide range of consumer products.
Read more on TPIA →